A novel spirocyclic scaffold accessed via tandem Claisen rearrangement/intramolecular oxa-Michael addition

  1. Anastasia Vepreva1,
  2. Alexander Yanovich2ORCID Logo,
  3. Dmitry Dar’in1ORCID Logo,
  4. Grigory Kantin1ORCID Logo,
  5. Alexander Bunev3ORCID Logo and
  6. Mikhail Krasavin1,4ORCID Logo

1Saint Petersburg State University, Saint Petersburg 199034, Russian Federation
2Academic Gymnasium of Saint Petersburg University, Saint Petersburg 199155, Russian Federation
3Medicinal Chemistry Center, Togliatti State University, Togliatti 445020, Russian Federation

4Immanuel Kant Baltic Federal University, Kaliningrad 236016, Russian Federation

  1. Corresponding author email

Associate Editor: T. J. J. Müller
Beilstein J. Org. Chem. 2022, 18, 1649–1655. https://doi.org/10.3762/bjoc.18.177
Received 10 Oct 2022, Accepted 11 Nov 2022, Published 06 Dec 2022

A non-peer-reviewed version of this article has been posted as a preprint https://doi.org/10.3762/bxiv.2022.83.v1

Abstract

A straightforward access to novel spiro[benzofuran-2,3'-pyrrolidine]-2',5'-diones based on the Rh2(esp)2-catalyzed insertion of carbenes derived from diazo arylidene succinimides (DAS) into the O–H bond of phenols is described. The initial adducts underwent a thermally promoted Claisen rearrangement followed by DABCO-catalyzed intramolecular 5-exo-trig oxa-Michael addition.

Keywords: Claisen rearrangement; diazo arylidene succinimides; intramolecular oxa-Michael addition; rhodium(II) carbene O–H insertion; spirocycles

Introduction

Spirocycles undoubtedly occupy a special place in drug design [1] and, in general, spirocyclic compounds intended for the interrogation of biological targets have been associated with higher success rates [2] in discovering new cases of affinity towards a three-dimensional protein molecule [3]. Spirocycles of all sorts are omnipresent in the natural product realm [4]. Among the approved medicines the following spirocyclic molecules are notable: spironolactone for heart disease and hypertention [5], buspirone for anxiety disorders [6], cevimeline for dry mouth and dry eye syndrome [7], fluspirilene for schizophrenia [8] and ilbesartan for hypertention and diabetic nephropathy [9], to mention a few (Figure 1).

[1860-5397-18-177-1]

Figure 1: Examples of approved spirocyclic drugs.

Hence the development of novel synthetic methods to construct spirocycles [10-14] constitutes a distinctly worthy undertaking which may as well influence the outlook of the novel medicines discovered and developed in the future.

Recently, we described a novel Rh(II)-catalyzed spirocyclizations involving diazo arylidene succinimide (DAS, such as 1a) with cyclohexanone (as well as other cyclic ketones) which delivered spiro-annulated 2-benzoxepines (such as 2a) along with a minor byproduct 3a identified by 1H NMR as the product of formal insertion of the rhodium(II) carbene species into the O–H bond of cyclohexanone enol form. This minor byproduct, on heating at 50 °C for 12 h, underwent the Claisen rearrangement to give diastereomerically pure maleimide 4a in 4% yield [15]. While for our study at the time the formation of 3 and 4 were viewed as a minor side-reaction, later be started pondering the possibility of giving the observed transformation a stronger impetus from the synthetic point of view. Specifically, we wanted to see if Rh(II)-catalyzed insertion of DAS-derived carbenes could be performed into the O–H bond of phenols and if the resulting phenoxy-substituted succinimides 5 could also undergo a Claisen rearrangement. The products of the latter (6) would again have a reactive phenolic hydroxy group which could potentially be involved in post-condensational transformations such as intramolecular oxa-Michael addition (Scheme 1). Herein, we report our findings obtained in the course of investigating the viability of this strategy.

[1860-5397-18-177-i1]

Scheme 1: (a) Earlier reported Rh(II)-catalyzed spirocyclization of DAS with the formation of minor enol ether product 3a and its Claisen rearrangement. (b) Synthetic strategy investigated in this work.

Results and Discussion

The initial attempt to involve DAS 1b in the Rh2(esp)2-catalyzed insertion reaction with 4-(tert-butyl)phenol was successful. The initial adduct 5b was not purified and was heated at 140 °C in toluene to give compound 6b in 47% yield over two steps (Scheme 2). No further optimization of the reaction conditions was undertaken except for the isolation for the initial O–H insertion product which facilitated subsequent steps (the Claisen rearrangement and the final cyclization, vide infra).

[1860-5397-18-177-i2]

Scheme 2: Initial attempt at Rh(II)-catalyzed O–H insertion/Claisen rearrangement.

With product 6a at hand we proceeded studying its base-promoted Michael-type cyclizations. As it follows from the data collated in Table 1, to our delight, cyclizations of the phenoxide anion generated on the action of base (except for 2,6-lutidine) proceeded as 5-exo-trig (rather than 6-endo-trig) process and yielded spirocyclic compound 7a as a mixture of syn and anti diastereomers. DABCO in toluene at room temperature over 1 h (Table 1, entry 5) gave a superior result both in terms of the isolated yield and diastereoselectivity. Increasing the polarity of the solvent appeared to be detrimental to the reaction outcome.

Table 1: Investigation of base-catalyzed transformation of compound 6a.

[Graphic 1]
Entry Solvent Base (30 mol %) T (°C) Total yield (%) syn/anti Conversion within 1 h (%)
1 toluene DABCO 0 34 79:21 70
2 toluene DBU 25 63 62:38 100
3 toluene Cs2CO3 25 66 73:27 100
4 toluene 2,6-lutidine 25
5 toluene DABCO 25 71 81:19 100
6 acetonitrile DABCO 25 66 77:23 100
7 methanol DABCO 25 48 46:54 100
8 MeOH/H2O (1:1) DABCO 25

With the conditions identified for the Rh2(esp)2-catalyzed insertion into the phenolic O–H bond, the Claisen rearrangement and the base-catalyzed cyclization to the spirocyclic product, we experimented with attempts to perform all three steps in a one-pot format. This gave inferior results in terms of product yield and purity. The best result was obtained by performing the Rh(II)-catalyzed insertion first, purifying the respective product 5 and then engaging it in the sequential Claisen rearrangement cyclization reactions performed in one-pot format.

To expand the scope of the newly discovered transformations, several products of the Rh(II)-catalyzed O–H insertions 5 were synthesized as detailed in Scheme 3.

[1860-5397-18-177-i3]

Scheme 3: Rh2(esp)2-catalyzed O–H insertion reactions between various DAS 1 and phenols.

The O–H insertion reaction worked well for electron-neutral or electron-rich phenols. The presence of chlorine substituents (such as 4-Cl or 2,4-diCl) in the phenol component drastically diminished the yield and led to the formation of the earlier reported DAS dimer [16]. Similarly, electron-donating groups (such as 4-methoxy) in the arylidene portion of 1 complicated the course of the reaction.

Having amassed a sizable arsenal of O–H insertion products 5a–n, we proceeded to study their behavior in the two-step, one-pot sequence of the Claisen rearrangement/intramolecular Michael-type spirocyclization as detailed in Scheme 4. In two cases (7a and 7c), the major (syn) and minor (anti) diastereomers were separated chromatographically and characterized. In one case (7a), the structure of the major (syn) diastereomer was unequivocally confirmed by single-crystal X-ray crystallography. In all other cases, only the pure syn diastereomer was isolated and characterized. The yields of spirocyclic products were generally modest to good over two steps. An electron-accepting group in the benzylidene portion (5j) or an N-benzyl substitution in the starting material (5g) lowered the reactivity and the Claisen rearrangement step was performed at a higher (150 °C) temperature.

[1860-5397-18-177-i4]

Scheme 4: Two-step, one-pot sequence of the Claisen rearrangement/intramolecular Michael-type spirocyclization of substrates 5a–l. The Claisen rearrangement product was not isolated. Scale from 0.3 to 0.9 mmol; pure major syn diastereomer was isolated and characterized in all cases; ain these examples, pure minor anti diastereomer was isolated and characterized; bthe structure was confirmed by crystallography. csyn/anti ratio is shown in parentheses; dthe reaction was performed at 150 °C.

Notable was our inability to involve o-methoxy- (5n) and (p-methoxy)phenoxy (5m) substrates in the two-step synthesis of the respective spirocycles 7. In both cases, 1H NMR analysis of the reaction mixture indicated the formation of complex product mixtures at the Claisen rearrangement step.

3,5-Dimethylphenoxy-substituted substrate 5h gave the best diastereomeric ratio in the series. The preference for the formation of the syn diastereomer in each case (and for 5a7a in particular) can, in principle, be rationalized by the greater steric repulsion in the conformer of the respective oxyanion leading to the anti diastereomer compared to that from which the major, syn diastereomer is formed (Scheme 5).

[1860-5397-18-177-i5]

Scheme 5: Tentative rationalization of the diastereoselectivity observed in all 57 transformations (shown for 5a7a).

Notably, a compound analogous to 5a was synthesized with thiophenol in 78% yield. However, it turned out to be completely unreactive towards the Claisen rearrangement step, even at 150 °C in 1,2-dichlorobenzene. Raising the temperature to 200 °C led to starting material deterioration and was not productive either.

Spirocyclic products 7a–l were tested for their ability to influence the survival of MDA-MB-231 (breast adenocarcinoma) and NCI-H460 (lung cancer) cell lines and proved completely non-cytotoxic. This validates these new compounds as suitable molecular probes for interrogating various biological targets via screening in cell-based assays.

Conclusion

We have developed a straightforward access to novel spiro[benzofuran-2,3'-pyrrolidine]-2',5'-diones based on Rh2(esp)2-catalyzed insertion of carbenes derived from α-diazosuccinimides (DAS) into the O–H bond of phenols. The initial adducts underwent a thermally promoted Claisen rearrangement followed by a DABCO-catalyzed intramolecular 5-exo-dig Michael addition. The resulting spirocyclic compounds are formed with a clear preference to the syn diastereomer over anti which can be rationalized by conformational analysis of the Claisen rearrangement precursors to their formation.

Supporting Information

Deposition number 2166113 (for syn-7a) contains the supplementary crystallographic data for this paper. These data are provided free of charge by the joint Cambridge Crystallographic Data Centre and Fachinformationszentrum Karlsruhe Access Structures service http://www.ccdc.cam.ac.uk/structures.

Supporting Information File 1: General experimental information, X-ray crystallographic data, synthetic procedures, analytical data and NMR spectra for the reported compounds.
Format: PDF Size: 3.5 MB Download

Acknowledgements

We thank the Research Center for Magnetic Resonance, the Center for Chemical Analysis and Materials Research, and the Center for X-ray Diffraction Methods of Saint Petersburg State University Research Park for obtaining the analytical data.

Funding

This research was supported by the Russian Foundation for Basic Research (# 21-53-12001).

References

  1. Hiesinger, K.; Dar’in, D.; Proschak, E.; Krasavin, M. J. Med. Chem. 2021, 64, 150–183. doi:10.1021/acs.jmedchem.0c01473
    Return to citation in text: [1]
  2. Zheng, Y.; Tice, C. M.; Singh, S. B. Bioorg. Med. Chem. Lett. 2014, 24, 3673–3682. doi:10.1016/j.bmcl.2014.06.081
    Return to citation in text: [1]
  3. Zheng, Y.-J.; Tice, C. M. Expert Opin. Drug Discovery 2016, 11, 831–834. doi:10.1080/17460441.2016.1195367
    Return to citation in text: [1]
  4. Chupakhin, E.; Babich, O.; Prosekov, A.; Asyakina, L.; Krasavin, M. Molecules 2019, 24, 4165. doi:10.3390/molecules24224165
    Return to citation in text: [1]
  5. Garthwaite, S. M.; McMahon, E. G. Mol. Cell. Endocrinol. 2004, 217, 27–31. doi:10.1016/j.mce.2003.10.005
    Return to citation in text: [1]
  6. Loane, C.; Politis, M. Brain Res. 2012, 1461, 111–118. doi:10.1016/j.brainres.2012.04.032
    Return to citation in text: [1]
  7. Ono, M.; Takamura, E.; Shinozaki, K.; Tsumura, T.; Hamano, T.; Yagi, Y.; Tsubota, K. Am. J. Ophthalmol. 2004, 138, 6–17. doi:10.1016/j.ajo.2004.02.010
    Return to citation in text: [1]
  8. van Epen, J. H. Psychiatr., Neurol., Neurochir. 1970, 73, 277–284.
    Return to citation in text: [1]
  9. Fischer, J.; Robin, G. C. Analogue-based Drug Discovery; Wiley-VCH: Weinheim, Germany, 2006; p 470. doi:10.1002/3527608001
    Return to citation in text: [1]
  10. Ammon, E.; Villinger, A.; Ehlers, P.; Langer, P. Synlett 2022, 33, 1633–1636. doi:10.1055/s-0042-1751363
    Return to citation in text: [1]
  11. Iaroshenko, V. O.; Dudkin, S.; Sosnovskikh, V. Ya.; Villinger, A.; Langer, P. Synthesis 2013, 45, 971–977. doi:10.1055/s-0032-1318273
    Return to citation in text: [1]
  12. Attanasi, O. A.; Favi, G.; Giorgi, G.; Mantellini, F.; Karapetyan, V.; Langer, P. Tetrahedron 2009, 65, 5456–5461. doi:10.1016/j.tet.2009.04.018
    Return to citation in text: [1]
  13. Rasool, N.; Rashid, M. A.; Adeel, M.; Görls, H.; Langer, P. Tetrahedron Lett. 2008, 49, 2254–2257. doi:10.1016/j.tetlet.2008.02.036
    Return to citation in text: [1]
  14. Rasool, N.; Rashid, M. A.; Reinke, H.; Fischer, C.; Langer, P. Tetrahedron 2008, 64, 3246–3252. doi:10.1016/j.tet.2008.01.066
    Return to citation in text: [1]
  15. Vepreva, A.; Kantin, G.; Krasavin, M.; Dar’in, D. Synthesis 2022, 54, 5128–5138. doi:10.1055/s-0037-1610790
    Return to citation in text: [1]
  16. Vepreva, A.; Bunev, A. S.; Kudinov, A. Yu.; Kantin, G.; Krasavin, M.; Dar’in, D. Beilstein J. Org. Chem. 2022, 18, 533–538. doi:10.3762/bjoc.18.55
    Return to citation in text: [1]

© 2022 Vepreva et al.; licensee Beilstein-Institut.
This is an open access article licensed under the terms of the Beilstein-Institut Open Access License Agreement (https://www.beilstein-journals.org/bjoc/terms), which is identical to the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0). The reuse of material under this license requires that the author(s), source and license are credited. Third-party material in this article could be subject to other licenses (typically indicated in the credit line), and in this case, users are required to obtain permission from the license holder to reuse the material.

 
Back to Article List

Other Beilstein-Institut Open Science Activities

Keep Informed

RSS Feed

Subscribe to our Latest Articles RSS Feed.

Subscribe

Follow the Beilstein-Institut

LinkedIn

Twitter: @BeilsteinInst